Literature DB >> 11201070

Phencyclidine (PCP)-induced deficits of prepulse inhibition in monkeys.

G S Linn1, D C Javitt.   

Abstract

Prepulse inhibition (PPI) of the acoustic startle reflex is a measure of sensorimotor gating which occurs in both rodents and humans. PPI is deficient in severe neuropsychiatric disorders such as schizophrenia. We investigated PPI in 10 adult monkeys (Cebus apella). Stimuli were 115 dB white noise startle pulses, either alone or preceded by 120 ms with a prepulse of either 8 or 16 dB above the 70 dB background noise. Experiments included a pretreatment baseline session and a session following treatment with either phencyclidine (PCP, 0.12 mg/kg, i.m.) or saline. Comparison of peak amplitudes indicated a significant intensity-dependent decrease in startle response that was similar to that observed in humans under similar experimental conditions. PCP treatment significantly disrupted PPI, but did not reduce responses to startle pulses alone. These results provide the first demonstration of PPI in monkeys. The ability of PCP to induce schizophrenia-like deficits in PPI suggests that PPI in nonhuman primates may provide an important animal model for the development of novel anti-schizophrenia medications.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11201070     DOI: 10.1097/00001756-200101220-00031

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  21 in total

1.  Effects of ayahuasca on binocular rivalry with dichoptic stimulus alternation.

Authors:  E Frecska; K D White; L E Luna
Journal:  Psychopharmacology (Berl)       Date:  2004-01-08       Impact factor: 4.530

2.  Activation of a nitric-oxide-sensitive cAMP pathway with phencyclidine: elevated hippocampal cAMP levels are temporally associated with deficits in prepulse inhibition.

Authors:  Daniel Klamer; Erik Pålsson; Kim Fejgin; Jianhua Zhang; Jörgen A Engel; Lennart Svensson
Journal:  Psychopharmacology (Berl)       Date:  2004-12-24       Impact factor: 4.530

3.  PSD-95 is essential for hallucinogen and atypical antipsychotic drug actions at serotonin receptors.

Authors:  Atheir I Abbas; Prem N Yadav; Wei-Dong Yao; Margaret I Arbuckle; Seth G N Grant; Marc G Caron; Bryan L Roth
Journal:  J Neurosci       Date:  2009-06-03       Impact factor: 6.167

4.  Moderate-level prenatal alcohol exposure enhances acoustic startle magnitude and disrupts prepulse inhibition in adult rhesus monkeys.

Authors:  Mary L Schneider; Julie A Larson; Craig W Rypstat; Leslie M Resch; Andrew Roberts; Colleen F Moore
Journal:  Alcohol Clin Exp Res       Date:  2013-06-13       Impact factor: 3.455

Review 5.  Towards medication-enhancement of cognitive interventions in schizophrenia.

Authors:  Hsun-Hua Chou; Elizabeth Twamley; Neal R Swerdlow
Journal:  Handb Exp Pharmacol       Date:  2012

Review 6.  Management of negative symptoms of schizophrenia.

Authors:  D C Javitt
Journal:  Curr Psychiatry Rep       Date:  2001-10       Impact factor: 5.285

7.  Somatic and neuroendocrine responses to standard and biologically salient acoustic startle stimuli in monkeys.

Authors:  Karen J Parker; Shellie A Hyde; Christine L Buckmaster; Serena M Tanaka; Katharine K Brewster; Alan F Schatzberg; David M Lyons; Steven H Woodward
Journal:  Psychoneuroendocrinology       Date:  2011-05       Impact factor: 4.905

8.  Reversal of phencyclidine-induced prepulse inhibition deficits by clozapine in monkeys.

Authors:  Gary S Linn; Shobhit S Negi; Scott V Gerum; Daniel C Javitt
Journal:  Psychopharmacology (Berl)       Date:  2003-07-04       Impact factor: 4.530

Review 9.  Animal models of working memory: insights for targeting cognitive dysfunction in schizophrenia.

Authors:  Stacy A Castner; Patricia S Goldman-Rakic; Graham V Williams
Journal:  Psychopharmacology (Berl)       Date:  2004-01-20       Impact factor: 4.530

10.  Habituation of acoustic startle is disrupted by psychotomimetic drugs: differential dependence on dopaminergic and nitric oxide modulatory mechanisms.

Authors:  Daniel Klamer; Erik Pålsson; Aron Revesz; Jörgen A Engel; Lennart Svensson
Journal:  Psychopharmacology (Berl)       Date:  2004-06-02       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.